Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required)
Funding Opportunity PAR-19-235 from the NIH Guide for Grants and Contracts. Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - April 2, 2019 Category: Research Source Type: funding
Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required)
Funding Opportunity PAR-18-233 from the NIH Guide for Grants and Contracts. Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Compared to traditional treatment approaches, programs that integrate pharmacologic, psychological, and rehabilitation interventions for FEP, i.e., team-based Coordinated Specialty Care (C...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 21, 2017 Category: Research Source Type: funding
Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required)
Funding Opportunity PAR-18-232 from the NIH Guide for Grants and Contracts. Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Compared to traditional treatment approaches, programs that integrate pharmacologic, psychological, and rehabilitation interventions for FEP, i.e., team-based Coordinated Specialty Care (C...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 21, 2017 Category: Research Source Type: funding
Early Stage Testing of Pharmacologic or Device -based Interventions for the Treatment of Mental Health Disorders (R33- Clinical Trial Required)
Funding Opportunity RFA-MH-18-703 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic crit...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 14, 2017 Category: Research Source Type: funding
Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33-Clinical Trial Required)
Funding Opportunity RFA-MH-18-702 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action, or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic cri...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 14, 2017 Category: Research Source Type: funding
Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33)
Funding Opportunity ID: 290627 Opportunity Number: RFA-MH-17-602 Opportunity Title: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: GrantCategory of Funding Activity: HealthCategory Explanation: CFDA Number(s): 93.242Eligible Applicants: State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Fe...
Source: Grants.gov - December 13, 2016 Category: Research Tags: Health Source Type: funding
Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33)
Funding Opportunity ID: 290644 Opportunity Number: RFA-MH-17-600 Opportunity Title: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: GrantCategory of Funding Activity: HealthCategory Explanation: CFDA Number(s): 93.242Eligible Applicants: State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments...
Source: Grants.gov - December 13, 2016 Category: Research Tags: Health Source Type: funding
Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33)
Funding Opportunity RFA-MH-17-602 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g. schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder, etc.). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 13, 2016 Category: Research Source Type: funding
Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33)
Funding Opportunity RFA-MH-17-600 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action, or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g. schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder, etc.). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnosti...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 13, 2016 Category: Research Source Type: funding
Reducing the Duration of Untreated Psychosis in the United States (R01)
Funding Opportunity Number: PAR-16-265 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: HealthCFDA Number: 93.242Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with the IRS,...
Source: Grants.gov - May 18, 2016 Category: Research Tags: Health Source Type: funding
Reducing the Duration of Untreated Psychosis in the United States (R34)
Funding Opportunity Number: PAR-16-264 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: HealthCFDA Number: 93.242Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with the IRS,...
Source: Grants.gov - May 18, 2016 Category: Research Tags: Health Source Type: funding
Reducing the Duration of Untreated Psychosis in the United States (R01)
Funding Opportunity PAR-16-265 from the NIH Guide for Grants and Contracts. Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Compared to traditional treatment approaches, programs that integrate pharmacologic, psychological, and rehabilitation interventions for FEP, i.e., team-based Coordinated Specialty Care...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 17, 2016 Category: Research Source Type: funding
Reducing the Duration of Untreated Psychosis in the United States (R34)
Funding Opportunity PAR-16-264 from the NIH Guide for Grants and Contracts. Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Compared to traditional treatment approaches, programs that integrate pharmacologic, psychological, and rehabilitation interventions for FEP, i.e., team-based Coordinated Specialty Care...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 17, 2016 Category: Research Source Type: funding
Cognitive Neuroscience
Funding Opportunity Number: PD-15-1699 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: Science and Technology and other Research and DevelopmentCFDA Number: 47.075Eligible Applicants Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"Agency Name: NSFClosing Date: Aug 13, 2015Award Ceiling: Expected Number of Awards: 25Creation Date: Apr 15, 2015Funding Opportunity Description: I. INTRODUCTION
The National Science Foundation announces the are...
Source: Grants.gov - April 15, 2015 Category: Research Tags: Science and Technology and other Research and Development Source Type: funding
Alexander Gralnick Research Investigator Prize
$20,000 to support exceptional research and mentoring accomplishments in the area of serious mental illness. Deadline: April 15, 2016 Sponsor: American Psychological Foundation The $20,000 grant supports “exceptional individuals working in the area of serious mental illness,” including but not limited to schizophrenia, bipolar disorder and paranoia (delusional disorder). The American Psychological Foundation provides financial support for innovative research and programs that enhance the power of psychology to elevate the human condition and advance human potential both now and in generatio...
Source: ScanGrants feed - November 14, 2014 Category: Research Authors: American Psychological Foundation Source Type: funding
